Novavax (United States)

Novavax (United States)

Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company's first and only commercial product is the Novavax COVID-19 vaccine. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Novavax (United States), United States, covering academic research published from 2000 to 2024. Read More.


Open Access Percentage

81%


Total
Publications

313


Total Open
Publications

255


Total
Citations

13K


Open Access
Percentage

81%


Total
Publications

313


Total Open
Publications

255


Total
Citations

13K

Wikipedia

Website

download

Breakdown

17% 39% 25% 19%

Publisher Open

17%

Both

39%

Other Platform Open

25%

Closed

19%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

0510152025303540455055Total Publications
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

56%OA Journal

OA Journal 56%

97

Hybrid 26%

45

No Guarantees 18%

32

Other Platform Open

Domain 66%

133

Preprint 24%

48

Institution 16%

33

Other Internet 16%

33

Public 3%

6

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
132
DOI
Other Internet
33
medRxiv
Preprint
28
bioRxiv
Preprint
16
Europe PMC
Domain
10
Royal Netherlands Academy of Arts and Sciences
Institution
8
Le Centre pour la Communication Scientifique Directe - HAL - Diderot
Institution
5
Figshare
Public
5
University of Padua
Institution
3
University of Oxford
Institution
3
1 / 4

Data updated 18 August 2025

Share

Share

Share